Phaseline

Companies › Abivax

Abivax: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Immunology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Obefazimod (ABX464)
Cap binding complex modulator
NCBP2, NCBP1Phase 3Ulcerative Colitis; Moderately to Severely Active Crohn Disease; HealthyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07453784Obefazimod (ABX464)Phase 1HealthyOtherSep 2026
NCT06456593Obefazimod (ABX464)Phase 2Moderately to Severely Active Crohn DiseaseImmunologyDec 2026
NCT05177835Obefazimod (ABX464)Phase 2Ulcerative ColitisImmunologyMar 2028
NCT05535946Obefazimod (ABX464)Phase 3Ulcerative ColitisImmunologyMay 2030

From the company's SEC filings

Cash and short-term investments of 538m EUR on 2025-12-31; operating cash outflow about 162m EUR a year; runway about 40 months at that burn, to Apr 2029; 2 of 3 coming phase 2-3 readouts fall inside that runway

Targets

NCBP2 (1) NCBP1 (1)

Companies with the same targets

–

Companies built like this

Zhejiang Wenda Pharma Technology Shattuck Labs Veradermics Palvella Therapeutics Oruka Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.